These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29801713)

  • 1. Awareness of Fabry disease in cardiology: A gap to be filled.
    Brito D; Cardim N; Lopes LR; Belo A; Mimoso J; Gonçalves L; Madeira H;
    Rev Port Cardiol (Engl Ed); 2018 Jun; 37(6):457-466. PubMed ID: 29801713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.
    Savostyanov K; Pushkov A; Zhanin I; Mazanova N; Trufanov S; Pakhomov A; Alexeeva A; Sladkov D; Asanov A; Fisenko A
    Orphanet J Rare Dis; 2022 May; 17(1):199. PubMed ID: 35578305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of left atrial size and function in hypertrophic cardiomyopathy and in Fabry disease with left ventricular hypertrophy.
    Saccheri MC; Cianciulli TF; Challapa Licidio W; Lax JA; Beck MA; Morita LA; Gagliardi JA;
    Echocardiography; 2018 May; 35(5):643-650. PubMed ID: 29457264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac Anderson-Fabry disease: lessons from a 25-year-follow up.
    Brito D; Miltenberger-Miltenyi G; Moldovan O; Navarro C; Madeira HC
    Rev Port Cardiol; 2014 Apr; 33(4):247.e1-7. PubMed ID: 24830310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fabry disease presenting as apical left ventricular hypertrophy in a patient carrying the missense mutation R118C.
    Caetano F; Botelho A; Mota P; Silva J; Leitão Marques A
    Rev Port Cardiol; 2014 Mar; 33(3):183.e1-5. PubMed ID: 24661928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance.
    Smid BE; van der Tol L; Cecchi F; Elliott PM; Hughes DA; Linthorst GE; Timmermans J; Weidemann F; West ML; Biegstraaten M; Lekanne Deprez RH; Florquin S; Postema PG; Tomberli B; van der Wal AC; van den Bergh Weerman MA; Hollak CE
    Int J Cardiol; 2014 Dec; 177(2):400-8. PubMed ID: 25442977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy.
    Sadasivan C; Chow JTY; Sheng B; Chan DKH; Fan Y; Choi PCL; Wong JKT; Tong MMB; Chan TN; Fung E; Kam KKH; Chan JYS; Chi WK; Paterson DI; Senaratne M; Brass N; Oudit GY; Lee APW
    PLoS One; 2020; 15(9):e0239675. PubMed ID: 32987398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy.
    Terryn W; Deschoenmakere G; De Keyser J; Meersseman W; Van Biesen W; Wuyts B; Hemelsoet D; Pascale H; De Backer J; De Paepe A; Poppe B; Vanholder R
    Int J Cardiol; 2013 Sep; 167(6):2555-60. PubMed ID: 22805550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.
    Chimenti C; Pieroni M; Morgante E; Antuzzi D; Russo A; Russo MA; Maseri A; Frustaci A
    Circulation; 2004 Aug; 110(9):1047-53. PubMed ID: 15313943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fabry disease in cardiology practice: Literature review and expert point of view.
    Hagège A; Réant P; Habib G; Damy T; Barone-Rochette G; Soulat G; Donal E; Germain DP
    Arch Cardiovasc Dis; 2019 Apr; 112(4):278-287. PubMed ID: 30826269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of Electrocardiography to Distinguish Fabry Disease from Sarcomeric Hypertrophic Cardiomyopathy.
    Antezana-Chavez E; Cianciulli TF; Hadid CL; Toro DD; Celano L; Saccheri MC; Baez KG; Lopez CA; Labadet CD; Gagliardi JA
    Am J Cardiol; 2022 Sep; 178():131-136. PubMed ID: 35810008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Fabry Disease in patients with left ventricular hypertrophy in Turkey: Multicenter study (LVH-TR subgroup analysis).
    Güzel T; Çağlar FNT; Ekici B; Kış M; Öztaş S; Öz A; Gök G; Kolak Z; Akşit E; Sarıca SA; Bayrak M; Birdal O; Uğuz B; Gitmez M; Berk Gİ; Oğuz M; Çalık AN; Kılıç S; Zoghi M; Ergene AO
    Int J Cardiovasc Imaging; 2023 Jun; 39(6):1143-1155. PubMed ID: 36920623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy.
    Gaggl M; Lajic N; Heinze G; Voigtländer T; Sunder-Plassmann R; Paschke E; Fauler G; Sunder-Plassmann G; Mundigler G
    Int J Med Sci; 2016; 13(5):340-6. PubMed ID: 27226774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Clinical Characteristics of Fabry Disease in Chinese Patients With Hypertrophic Cardiomyopathy.
    Xiao Y; Sun Y; Tian T; Wang TJ; Zhao RX; Zhang Y; Wang LP; Liu YX; Lu CX; Zhou XL; Yang WX
    Am J Med Sci; 2021 Sep; 362(3):260-267. PubMed ID: 34266644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLA Gene Mutation in Hypertrophic Cardiomyopathy with a New Variant Description: Is it Fabry's Disease?
    Chaves-Markman ÂV; Markman M; Calado EB; Pires RF; Santos-Veloso MAO; Pereira CMF; Lordsleem ABMDS; Lima SG; Markman Filho B; Oliveira DC
    Arq Bras Cardiol; 2019 Jul; 113(1):77-84. PubMed ID: 31291414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic dilemmas in Fabry disease: a case series study on GLA mutations of unknown clinical significance.
    Smid BE; Hollak CE; Poorthuis BJ; van den Bergh Weerman MA; Florquin S; Kok WE; Lekanne Deprez RH; Timmermans J; Linthorst GE
    Clin Genet; 2015 Aug; 88(2):161-6. PubMed ID: 25040344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Asian Fabry Cardiomyopathy High-Risk Screening Study 2 (ASIAN-FAME-2): Prevalence of Fabry Disease in Patients with Left Ventricular Hypertrophy.
    Leung SP; Dougherty S; Zhang XY; Kam KKH; Chi WK; Chan JYS; Fung E; Wong JKT; Choi PCL; Chan DKH; Sheng B; Lee AP
    J Clin Med; 2024 Jul; 13(13):. PubMed ID: 38999464
    [No Abstract]   [Full Text] [Related]  

  • 18. Late-onset Fabry disease: the cardiac sequela.
    Tremblay J; Kim S; Philbin E; Beers K; Lightle A; Belov D
    BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35680278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation between Fabry disease and hypertrophic cardiomyopathy with cardiac T1 mapping.
    Deborde E; Dubourg B; Bejar S; Brehin AC; Normant S; Michelin P; Dacher JN
    Diagn Interv Imaging; 2020 Feb; 101(2):59-67. PubMed ID: 31519470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy.
    Maron MS; Xin W; Sims KB; Butler R; Haas TS; Rowin EJ; Desnick RJ; Maron BJ
    Am J Med; 2018 Feb; 131(2):200.e1-200.e8. PubMed ID: 28943383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.